We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CBER Faults Drugmaker for Implying Hemophilia Drug Allows Patients to Engage in High-Risk Activity
CBER Faults Drugmaker for Implying Hemophilia Drug Allows Patients to Engage in High-Risk Activity
CBER’s advertising and promotional labeling branch sent an untitled letter to a drugmaker in Pennsylvania saying the company overpromised the impact of its hemophilia treatment.